Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). DBV Technologies's share price for the quarter that ended in Dec. 2023 was $0.9528. DBV Technologies's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 192.42 Mil. Therefore, DBV Technologies's market cap for the quarter that ended in Dec. 2023 was $183.34 Mil.
DBV Technologies's quarterly market cap
declined
from Jun. 2023 ($365.18 Mil) to Sep. 2023 ($261.33 Mil) and
declined
from Sep. 2023 ($261.33 Mil) to Dec. 2023 ($183.34 Mil).
DBV Technologies's annual market cap
increased
from Dec. 2021 ($175.81 Mil) to Dec. 2022 ($287.60 Mil) but then
declined
from Dec. 2022 ($287.60 Mil) to Dec. 2023 ($183.34 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. DBV Technologies's Enterprise Value for Today is $-5.74 Mil.
DBV Technologies Market Cap Historical Data
The historical data trend for DBV Technologies's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's Market Cap
For the Biotechnology subindustry, DBV Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Market Cap falls into.
DBV Technologies Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
DBV Technologies's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (NAS:DBVT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
DBV Technologies Market Cap Related Terms
Thank you for viewing the detailed overview of DBV Technologies's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies (DBV Technologies) Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 